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Background. The association between plasma omega-6 fatty acids and cardiovascular disease (CVD) is unclear, and discrepancy
remains concerning the cardiovascular beneﬁt of the omega-3 fatty acid alpha-linolenic acid. Methods. Associations of plasma
phospholipid fatty acid levels (arachidonic acid, linoleic acid, eicosapentaenoic acid, docosahexaenoic acid (DHA), and alpha-
linolenic acid) with cardiac magnetic resonance imaging measures of left ventricular (LV) mass, LV volume, ejection fraction,
stroke volume, and aortic distensibility were investigated in 1,274 adults. Results. Results of multivariate analysis showed no
statistically signiﬁcant associations of plasma omega-6 or omega-3 levels with cardiac magnetic resonance imaging measures.
Stratiﬁcation by gender revealed a positive association between DHA and LV mass in women (β = 1.89, P = 0.02; P interaction
= 0.003) and a trend for a positive association between DHA and ejection fraction in men (β = 0.009, P = 0.05; P interaction
= 0.03). Conclusion. Additional research is warranted to clarify the eﬀects of plasma DHA on cardiac structure and function in
women versus men.
1.Introduction
Contemporary work suggests that consumption of polyun-
saturated fatty acids (PUFAs), in place of saturated fats,
decreases the risk of cardiovascular disease (CVD) [1]. In
addition, dietary long-chain omega-3 PUFAs (eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), both
found in fatty ﬁsh) have been associated with measur-
able improvements in cardiac hemodynamics and function
as assessed by echocardiography. However, more accurate
objective measures assessing the relationship of PUFAs
and LV mass as well as LV mass/volume ratio (the latter
associated with both nonheart failure cardiovascular events
and diastolic dysfunction [2]) in human subjects are lacking.
Furthermore, similar associations among fatty acids other
than long-chain omega-3 PUFAs have not been deﬁned.
Thus, the purpose of this study is to determine the
associations between plasma phospholipid omega-6 PUFAs2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
(arachidonic acid (AA) and linoleic acid (LA)) and plasma
phospholipid omega-3 PUFAs (EPA, DHA, and ALA) with
cardiac magnetic resonance (CMR) measures of cardiovas-
cular structure and function, including aortic distensibility,
LV mass, LV mass/volume ratio, ejection fraction, and stroke
volume.
2.MaterialsandMethods
2.1. Study Population and Data Collection. MESA is a pro-
spective cohort study that began in July 2000 to investigate
the prevalence, correlates, and progression of subclinical
CVD in individuals without known CVD at baseline [3].
The main cohort included 6,814 women and men aged 45–
84 years old at baseline recruited from 6US communities.
MESA cohort participants were 38% white (n = 2624),
28% black (n = 1895), 22% Hispanic (n = 1492), and
12% Chinese (n = 803). A variety of noninvasive mea-
sures of subclinical disease, including magnetic resonance
imaging of cardiac structure and function, were obtained
from volunteers during the ﬁrst examination of the MESA
cohort (July 2000–August 2002). In the present study, we
excluded those who had missing data on both plasma
phospholipid fatty acids (n = 5,172) and CMR measures
(n = 4,404 for measures of LV mass, LV mass/volume
ratio, ejection fraction, and stroke volume; n = 5,136 for
aortic distensibility) as well as those with missing covariates
used in the study (n = 2). Because plasma phospholipid
fatty acids and CMR measures were secondary measures,
these assessments were not performed on the full cohort
at baseline. Total sample size of participants who had data
on plasma phospholipid measures, selected covariates, and
CMR measures of LV mass, LV mass/volume ratio, ejection
fraction, and stroke volume was 1,274. Total sample size of
subjects who had data on plasma phospholipid measures,
selected covariates, and CMR measures of aortic stiﬀness was
914. This study was approved by the Institutional Review
Boards of each study site, and written informed consent was
obtained from all participants.
2.2. Plasma Phospholipids Extraction. Fasting blood samples
were collected, and fatty acid analyses were performed at
the Collaborative Studies Clinical Laboratory at Fairview-
UniversityMedicalCenter(Minneapolis,Minn,USA)aspre-
viously described [3, 4]. In brief, plasma phospholipids were
extracted with chloroform/methanol, and thin layer chro-
matography was used to separate the lipid fractions. The
fattyacidsinthephospholipidfractionweretransmethylated
and separated by gas chromatography equipped with a ﬂame
ionization detector. The concentration of each fatty acid was
expressed as a percentage of total fatty acids. For statistical
analyses, plasma phospholipid fatty acids were divided into
quartiles.
2.3. Cardiac Magnetic Resonance Imaging Measures. CMR
imaging was performed with 1.5-T whole-body MRI sys-
tems, Signa CV/I or Signa LX (General Electric Medical
Systems), at the ﬁrst examination. Determination of LV
mass and volumes have been previously described and were
adjusted for body size [5]. LV mass was determined by
the summation of myocardial area (the diﬀerence between
endocardial and epicardial contour) times slice thickness
plus image gap in the end-diastolic phase multiplied by
the speciﬁc gravity of myocardium (1.05g/mL). LV end-
diastolic volume and LV end-systolic volume were calculated
by the summation of areas on each separate slice multiplied
by the summation of slice thickness and image gap. LV
stroke volume was calculated as the diﬀerence between
LV end-diastolic volume and LV end-systolic volume. LV
ejection fraction was calculated as LV stroke volume divided
by LV end-diastolic volume multiplied by 100.
Evaluation of aortic distensibility has also been previ-
ously described [6]. Images of the ascending and descending
aorta were acquired in the transverse plane at the level
of the right pulmonary artery perpendicular to the vessel
lumen. The following formula was used for calculation of
aortic distensibility: aortic distensibility = (maximum area
− minimum area)/[(Minimum area) × pulse pressure] ×
1000. The minimum and maximum cross-sectional areas
of the ascending aorta were determined using an auto-
mated contour routine using the software FLOW (Medis).
Pulse pressure was the diﬀerence between systolic and dias-
tolic measurements of blood pressure, obtained immediately
before and after the MRI aortic measurements while the
patient was in the supine position in the MRI scanner.
2.4. Statistical Analysis. Means and standard deviations or
proportions were calculated for selected variables according
to quartiles of plasma fatty acids (Table 1). For the pri-
maryanalysis,linearregressionmodelswereusedtoexamine
theassociationbetweenplasmaphospholipidfattyacidlevels
andCMRmeasuresofcardiovascularstructureandfunction.
Minimally adjusted (age, gender, race/ethnicity, and ﬁeld
center)and fullyadjusted models wereusedtoexamine these
relationships. A number of potential confounders for inclu-
sion in the fully adjusted models were evaluated based on
clinical relevance, previously published associations, or asso-
ciations with exposures or outcomes in the current data
set. For parsimony in model construction, covariates that
did not appreciably alter the relationship between plasma
fatty acids and CMR measures of cardiovascular structure
and function were excluded. The ﬁnal multivariable adjusted
model included age, gender, race/ethnicity, BMI, current
smoking status, education level, ﬁeld center, and total:HDL
cholesterol, systolic blood pressure, and total energy intake.
Asourpreviousworkhassuggestedagenderdiﬀerencein
the association between omega-3 fatty acids and endothelial
function [7]a n db e c a u s eg e n d e rd i ﬀerences in fatty acid
metabolism and tissue levels have been described [8–
11], we also chose to stratify analyses by gender. When
there appeared to be a signiﬁcant diﬀerence in plasma phos-
pholipid fatty acid levels and CMR measures, formal tests
for interaction were performed using the product of gender
× plasma phospholipid fatty acid in the model. Because fatty
acids have also been shown to have diﬀerential eﬀects on
vascular reactivity by age [12], we also explored whether
there were signiﬁcant diﬀerences in the relationship betweenJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
plasma phospholipid fatty acid levels and CMR measures
after stratiﬁcation by age (<65 years versus ≥65 years). All P
valueswere2-sided,andbecausemultipleexposure-outcome
tests were performed, a more stringent P value of < 0.01 was
considered statistically signiﬁcant. We used JMP version 8.0
(SAS Institute Inc., Cary, NC, USA) for analyses.
3. Results
3.1. Participant Characteristics. Characteristics of partici-
pants according to plasma phospholipid omega-6 fatty acid
LA and omega-3 fatty acid DHA quartiles are presented
in Table 1. The highest plasma phospholipid LA quartile
was associated with male gender, Chinese race/ethnicity,
lower BMI, lower blood lipid levels, lower prevalence of
diabetes diagnosis, lower alcohol intake, and less fruit intake
compared to the lower plasma phospholipid LA quartiles. In
comparison, the highest plasma phospholipid DHA quartile
was associated with older age, female gender, Chinese
race/ethnicity, lower BMI, higher education, less tobacco
use, lower systolic blood pressure, lower blood lipid levels,
higher cholesterol medication use, lower total energy intake,
lower alcohol intake, less saturated fat intake, and greater
cruciferous vegetable intake compared to the lower plasma
phospholipid DHA quartiles.
3.2. Plasma Omega-6 Fatty Acids and CMR Measures of Car-
diovascular Structure and Function. After adjustment for
age, gender, race/ethnicity, and site, plasma phospholipid
AA showed no association with LV mass, LV mass/volume
ratio, EF, stroke volume, or aortic distensibility as assessed
by CMR. These results were unchanged after adjustment
for additional covariates (Table 2). Plasma phospholipid LA
showed a statistically signiﬁcant inverse association with
ejection fraction in the minimally adjusted model (P =
0.001) with a trend for signiﬁcance in the fully adjusted
model (P = 0.02; Table 2), but this association was not
robust after additional adjustment for plasma phospholipid
saturated fatty acid levels (P = 0.07, data not shown). No
other signiﬁcant associations between plasma phospholipid
LA and CMR measures of cardiovascular structure and
function were found in either minimally or fully adjusted
models (Table 2). Stratiﬁcation by age and gender revealed
no heterogeneity in the relationship between either plasma
phospholipidAAorLAandCMRmeasuresofcardiovascular
structure and function (data not shown).
3.3. Plasma Omega-3 Fatty Acids and CMR Measures of Car-
diovascular Structure and Function. After adjustment for
age, gender, race/ethnicity, and site, plasma phospholipid
DHA showed no signiﬁcant association with LV mass, LV
mass/volume ratio, EF, stroke volume, or aortic distensibility
in either minimally or fully adjusted models (Table 3(a)).
Though trends for positive associations between plasma
phospholipid EPA and LV mass as well as stroke volume were
noted in minimally adjusted models (P = 0.02 and P = 0.03,
resp., data not shown), these associations became insigniﬁ-
cant after adjustment for additional covariates (Table 3(a)).
Similarly, plasma phospholipid ALA showed no statistically
signiﬁcant associations with LV mass, LV mass/volume ratio,
EF, stroke volume, or aortic distensibility as assessed by
CMR. These associations were unchanged after adjustment
for additional covariates (Table 3(b)), including adjustment
for other plasma fatty acids.
When analyses were stratiﬁed by gender, a trend for a
positive association was noted between plasma phospholipid
DHA and LV mass in women (P = 0.02; Figure 1(a))
but not in men, and a statistically signiﬁcant gender ×
DHA interaction was observed (P = 0.003; mean plasma
phospholipid fatty acid levels for each quartile by gender
are shown in Table 4). A similar pattern between plasma
phospholipid EPA and LV mass in women was observed, but
again, results were not statistically signiﬁcant (P = 0.06,
fully-adjusted model); tests for gender × EPA interactions
were also nonsigniﬁcant. In contrast to the ﬁndings noted
in women, higher plasma phospholipid DHA was associated
with a trend for increased ejection fraction in men (P =
0.05; Figure 1(b)); formal gender × DHA interaction tests
also showed a trend toward signiﬁcance (P = 0.03).
Finally, stratiﬁcation by age revealed no heterogeneity in
the relationship between plasma phospholipid omega-3 fatty
acid levels and CMR measures of cardiovascular structure
and function (data not shown).
4. Discussion
Plasma phospholipid polyunsaturated fatty acids are a mark-
er of dietary patterns, with higher proportions generally re-
ﬂecting greater consumption of polyunsaturated fats and less
cardiovascular disease. These data from 1,274 healthy, mul-
tiethnic volunteers corroborate this concept by showing
that men within higher plasma phospholipid DHA quartiles
(with quartiles two through four corresponding to average
intake of one or more servings of nonfried ﬁsh per week,
as compared with food frequency questionnaire data and as
supported by others [13, 14]) had modestly higher ejection
fractions compared to men within lower plasma phospho-
lipid DHA quartiles (quartile one corresponding to average
intake of less than one serving of nonfried ﬁsh per week.) In
contrast, women within higher plasma phospholipid DHA
quartiles demonstrated modestly higher LV mass compared
to women within lower plasma phospholipid DHA quartiles.
Though MRI measures of cardiac structure and function
are considered highly accurate and reproducible, the clinical
signiﬁcance of such small diﬀerences among a healthy
population remains unclear. Lastly, the present analysis does
not provide evidence of any signiﬁcant associations between
plasma phospholipid omega-6 or ALA PUFAs and CMR
measures of cardiovascular structure and function.
The beneﬁcial eﬀects of dietary EPA and DHA in preven-
tion of sudden cardiac death, acute coronary syndrome, and
heart failure are well documented [15–19]. Consumption of
long-chain omega-3 fatty acids has been associated with im-
provements in stroke volume, systemic vascular resistance,
and improved E/A ratio (a marker for diastolic dysfunction)4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Table 2: Relation between plasma phospholipid omega-6 fatty acid levels and measures of cardiac structure and function.‡,∗
Measure
Plasma AA (n)§ Plasma LA (n)§
Q1 Q2 Q3 Q4 P Q1 Q2 Q3 Q4 P
n = 319 n = 319 n = 320 n = 318 trend n = 324 n = 316 n = 318 n = 318 trend
Aortic distensibility,
10(−3)mmHg(−1)
1.25 1.25 1.22 1.23 0.4 1.23 1.25 1.24 1.23 0.98
LV mass, grams 143.3 144.4 145.8 143.8 0.62 144.2 144.4 145.7 142.8 0.69
LV mass:volume 0.12 0.11 0.11 0.14 0.64 0.13 0.13 0.12 0.12 0.70
Ejection fraction, % 68.32 68.05 68.01 68.61 0.67 68.99 68.66 67.52 68.01 0.02
Stroke volume, mL 84.92 86.10 86.82 83.86 0.64 86.30 85.32 85.57 84.27 0.20
‡Multivariate linear regression analysis with adjustment for age, gender, race/ethnicity, BMI, current smoking status, education level, site, and total: HDL
cholesterol, systolic blood pressure, and total energy intake.
∗AA, arachidonic acid; LA, linoleic acid; LV, left ventricular.
§Sample sizes are for each plasma phospholipid quartile associated with LV mass, LV mass/volume ratio, ejection fraction, and stroke volume.
Sample sizes for each plasma phospholipid quartile associated with aortic distensibility varied slightly due to fewer available aortic distensibility measures and
were as follows for AA: Q1 = 204, Q2 = 232, Q3 = 140, Q4 = 238 and for LA: Q1 = 255, Q2 = 227, Q3 = 223, Q4 = 209.
Table 3:(a) Relationbetweenplasmaphospholipidomega-3fattyacidlevelsandmeasuresofcardiacstructureandfunction.‡,∗ (b)Relation
between plasma phospholipid omega-3 fatty acid levels and measures of cardiac structure and function.‡,∗
(a)
Measure
Plasma EPA (n)§ Plasma DHA (n)§
Q1 Q2 Q3 Q4 P Q1 Q2 Q3 Q4 P
n = 305 n = 298 n = 334 n = 337 trend n = 292 n = 309 n = 327 n = 346 trend
Aortic distensibility,
10(−3)mmHg(−1) 1.22 1.26 1.23 1.26 0.26 1.23 1.22 1.26 1.26 0.17
LV mass, grams 143.14 143.61 146.48 145.38 0.14 144.14 142.19 145.45 147.19 0.07
LV mass:volume 0.12 0.12 0.14 0.12 0.31 0.12 0.12 0.13 0.14 0.21
Ejection fraction, % 67.94 68.50 68.22 68.68 0.26 68.13 68.82 68.35 68.53 0.29
Stroke volume, mL 84.52 85.93 85.15 87.04 0.12 84.67 85.56 85.47 86.55 0.27
‡Multivariate linear regression analysis with adjustment for age, gender, race/ethnicity, BMI, current smoking status, education level, site, and total: HDL
cholesterol, systolic blood pressure, and total energy intake.
∗EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ALA, alpha-linolenic acid; LV, left ventricular.
§Sample sizes are for each plasma phospholipid quartile associated with LV mass, LV mass/volume ratio, ejection fraction, and stroke volume.
Sample sizes for each plasma phospholipid quartile associated with aortic distensibility varied slightly due to fewer available aortic distensibility
measures and were as follows for EPA, Q1 = 225, Q2 = 212, Q3 = 245, Q4 = 232 and for DHA, QQ = 213, Q2 = 239, Q3 = 220, Q4 = 242.
(b)
Measure
Plasma ALA (n)§
Q1 Q2 Q3 Q4 P
n = 345 n = 318 n = 308 n = 303 trend
Aortic distensibility,
10(−3)mmHg(−1) 1.23 1.26 1.21 1.24 0.59
LV mass, grams 143.41 144.87 145.19 144.67 0.48
LV mass:volume 0.13 0.13 0.11 0.12 0.40
Ejection fraction, % 68.18 68.53 68.20 68.07 0.73
Stroke volume, mL 84.20 85.40 87.46 85.37 0.18
‡Multivariate linear regression analysis with adjustment for age, gender, race/ethnicity, BMI, current smoking status, education level, site, and total: HDL
cholesterol, systolicblood pressure, and total energy intake.
∗ALA, alpha-linolenic acid; LV, left ventricular.
§Sample sizes are for each plasma phospholipid quartile associated with LV mass, LV mass/volume ratio, ejection fraction, and stroke volume. Sample sizes
for each ALA quartile associated with aortic distensibility varied slightly due to fewer available aortic distensibility measures and were as follows: Q1 = 258,
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Table 4: Mean plasma phospholipid fatty acid quartile values, by gender.‡
Plasma fatty acid Men Women
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
AA 8.95 ± 0.18 10.70 ± 0.07 12.39 ± 0.07 15.21 ± 0.20 8.99 ± 0.17 10.61 ± 0.07 12.28 ± 0.07 15.18 ± 0.20
LA 17.46 ± 0.24 20.65 ± 0.10 22.74 ± 0.09 25.59 ± 0.31 17.37 ± 0.24 20.63 ± 0.09 22.70 ± 0.09 25.21 ± 0.29
EPA 0.4 ± 0.01 0.62 ± 0.01 0.95 ± 0.02 2.02 ± 0.25 0.41 ± 0.01 0.63 ± 0.01 0.93 ± 0.02 2.03 ± 0.25
DHA 2.54 ± 0.06 3.69 ± 0.04 4.76 ± 0.05 6.06 ± 0.22 2.64 ± 0.06 3.67 ± 0.04 4.77 ± 0.05 6.4 ± 0.22
ALA 0.10 ± 0.01 0.15 ± 0.01 0.19 ± 0.01 0.29 ± 0.02 0.10 ± 0.01 0.15 ± 0.01 0.19 ± 0.01 0.27 ± 0.02
‡Mean ± SE, expressed as %total plasma phospholipid fatty acids and adjusted for age, race/ethnicity, BMI, current smoking status, education level, site, total:
HDL cholesterol, systolic blood pressure, and total energy intake.
∗AA, arachidonic acid; LA, linoleic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ALA, alpha-linolenic acid.
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Figure 1: Relations between plasma phospholipid docosahexaenoic acid (DHA) levels, left ventricular (LV) mass, and ejection fraction,
by gender. Results shown are least squares means ± SD after adjustment for age, race/ethnicity, BMI, current smoking status, education
level, site, total:HDL cholesterol, systolic blood pressure, and total energy intake. Concentrations of plasma phospholipid fatty acid levels
(expressedaspercentagesoftotalfattyacids)includingDHAweresummedandrankedintoquartilesfromlowesttohighestbasedonsample
range. Signiﬁcant gender × DHA interactions were noted for both LV mass (P = 0.003) and ejection fraction (P = 0.03).
as assessed by echocardiography [20], and an inverse associ-
ation between plasma DHA and measures of arterial stiﬀness
including pulse wave velocity has been observed [21]. These
ﬁndings are biologically plausible, as experimental evidence
suggest that long-chain fatty acids may impact membrane
ﬂuidity, nitric oxide production, and/or shift of eicosanoid
pathways involved in inﬂammation and vasoconstriction
[22–25].
In contrast to the results in men, the observed pos-
itive association between plasma phospholipid DHA and
increased LV mass among women within in this cohort
initially appears surprising. However, there remains con-
siderable discrepancy in the literature regarding gender
diﬀerences in the association between PUFAs and cardio-
vascular outcomes. Among population-based cohorts, the
nurses’ health study demonstrated a signiﬁcantly nega-
tive association between ﬁsh consumption and incidence of
CHD, and the ARIC study showed an inverse relationship
in plasma phospholipid omega-3 fatty acids (particularly
DHA) and incident heart failure in women [26]. Conversely,J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
the Rotterdam study observed no relationship between ﬁsh
consumption and incident heart failure in a population of
predominantly women [27]. Other studies in women have
observed an inverse relationship between PUFA intake and
HDL cholesterol concentrations [28], evidence of atheroscle-
rotic progression [29], and nonsigniﬁcant trends toward
more CHD events and higher total mortality compared
to men [30]. In a previous report, we found that women
within the highest quartile of nonfried ﬁsh consumption
haddecreasedbrachialarteryﬂow-mediateddilation(FMD),
a noninvasive measure of endothelial function, compared
to women within the lowest quartile of nonfried ﬁsh con-
sumption [7].
Endothelial dysfunction is an independent predictor of
cardiovascular events [31, 32], and may induce an increased
in LV mass via increased systemic vascular resistance [33].
In addition, the eﬀects of estrogen (speciﬁcally, 17beta-
estradiol) on LV mass have been well established and po-
tentially include several mediators that may function via
multiple receptors [34–37]. One such mediator may include
the transcription factor sterol regulatory element-binding
protein-1 (SREBP-1) [38]. DHA is known to downregulate
production of SREBP-1, and others have shown that SREBP-
1 is involved in conversion of estrone to 17beta-estradiol
[39]. Thus perhaps elevated DHA levels, resulting in down-
regulationofSREBP-1withsubsequentdecreasedbioconver-
sion toward 17beta-estradiol, may result in adverse eﬀects on
vascular reactivity and/or LV remodeling. Future investiga-
tions including animal studies and/or in vitro models may
provide additional insight to the validity of this hypothesis.
The strengths of this study include the ethnically diverse
population, the inclusion of both men and women, and the
availabilityofobjectiveplasmaphospholipidfattyacidmeas-
ures as well as CMR measures of cardiovascular structure
and function. The limitations include the observational
cross-sectional study design with its known inability to
infer causation and potential for temporal bias, and like any
observational study, there remains the possibility of residual
confounding for factors (such as health status) that could
have meaningful impact on the observed results. It is also
recognized that plasma phospholipid fatty acid measures are
reﬂective of dietary intake over weeks, hence may not be
representative of long-term intake [40]. Lastly, though we
chose a more conservative ap r i o r iP value in an attempt
to correct for any ﬁndings that may be reﬂective of spuri-
ous associations resulting from multiple exposure-outcome
testing, the vast majority of our observations exceeded this
threshold, and must be interpreted with caution.
In conclusion, this study is the ﬁrst to examine the
relationship between plasma phospholipid fatty acid levels
andCMRmeasuresofcardiovascularstructureandfunction.
Within this cohort of mixed ethnic/racial groups without
known coronary artery disease, a gender diﬀerence was
suggested in the association between plasma phospholipid
DHA and ejection fraction: a positive association between
DHA and ejection fraction was observed in men but not
women, and a trend for a gender × DHA interaction
was noted. In addition, a positive association between
plasma phospholipid DHA and LV mass was found among
women but not men, and a statistically signiﬁcant gender
× DHA interaction was observed. Additional research is
warranted to clarify the eﬀects of omega-3 fatty acids
on cardiac structure and function in women versus men.
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